Pharmacogenetics of pain management in Zimbabwean patients with sickle cell disease.
Pharmacogenomics
; 24(7): 359-369, 2023 05.
Article
em En
| MEDLINE
| ID: mdl-37248824
ABSTRACT
Background:
Pain is a common cause of hospitalization in sickle cell disease (SCD) patients. Failure to effectively control pain remains a challenge in patient care. Materials &methods:
The authors conducted a cross-sectional study to determine the effect of CYP2D6 and UGT2B7 polymorphisms on pain management in 106 Zimbabwean SCD patients. Participant information was collected on a questionnaire. Genotyping was conducted using the GenoPharm® pharmacogenomics open array panel containing CYP2D6 and UGT genetic variants implicated in opioid response.Results:
The reduced function alleles CYP2D6*17 and *29 had high frequencies of 15.9% and 12.9%, respectively. UGT2B7 rs73823859 showed a statistically significant correlation with pain levels (p = 0.0454).Conclusion:
This study demonstrated the role of UGT2B7 polymorphism in SCD patient pain management.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Farmacogenética
/
Anemia Falciforme
Tipo de estudo:
Observational_studies
/
Prevalence_studies
/
Risk_factors_studies
Limite:
Humans
País/Região como assunto:
Africa
Idioma:
En
Revista:
Pharmacogenomics
Ano de publicação:
2023
Tipo de documento:
Article